Redefining Care for IDH-Mutant Low-Grade Gliomas: Clinical Implications of the INDIGO Trial and Updated Guidelines

Kristin S. Bartman, Katherine B. Peters

Open source

DOI
10.1016/j.clinme.2026.100644
Published
2026-09
Container
Clinical Medicine
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.clinme.2026.100644,
  title = {Redefining Care for IDH-Mutant Low-Grade Gliomas: Clinical Implications of the INDIGO Trial and Updated Guidelines},
  author = {Kristin S. Bartman and Katherine B. Peters},
  year = {2026},
  journal = {Clinical Medicine},
  doi = {10.1016/j.clinme.2026.100644},
  url = {https://doi.org/10.1016/j.clinme.2026.100644}
}

RIS

TY  - JOUR
TI  - Redefining Care for IDH-Mutant Low-Grade Gliomas: Clinical Implications of the INDIGO Trial and Updated Guidelines
AU  - Kristin S. Bartman
AU  - Katherine B. Peters
PY  - 2026
JO  - Clinical Medicine
DO  - 10.1016/j.clinme.2026.100644
UR  - https://doi.org/10.1016/j.clinme.2026.100644
ER  - 

APA

Bartman, K. S., & Peters, K. B. (2026). Redefining Care for IDH-Mutant Low-Grade Gliomas: Clinical Implications of the INDIGO Trial and Updated Guidelines. Clinical Medicine. https://doi.org/10.1016/j.clinme.2026.100644

Source records